Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    Why did this record match?
    Reference Devices :

    K241909

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Halyard Purple Nitrile-XTRA* Powder-Free Exam Gloves, Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Fentanyl Citrate in Simulated Gastric Acid are disposable devices intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

    The following chemotherapy drugs and concentration had NO breakthrough detected up to 240 minutes:

    • Arsenic Trioxide (1 mg/ml)
    • Bendamustine, (5 mg/ml)
    • Blenoxane (15 mg/ml)
    • Bleomycin (15 mg/ml)
    • Bortezomib (1 mg/ml)
    • Busulfan (6 mg/ml)
    • Carboplatln (10 mg/ml)
    • Carfilzomib (2 mg/ml)
    • Cetuximab (2 mg/ml)
    • Cisplatin (1 mg/ml)
    • Cyclophosphamide (Cytoxan) (20 mg/ml)
    • Cytarabine (100 mg/ml)
    • Dacarbazine (DTIC) {10 mg/ml)
    • Daunorubicin {5 mg/ml)
    • Decitabine (5 mg/ml)
    • Docetaxel (10 mg/ml)
    • Doxorubicin HCL (2 mg/ml)
    • Ellence (2 mg/ml)
    • Erbitux (2 mg/ml)
    • Eribilin Mesylate (0.5 mg/ml)
    • Etoposide (Toposar) (20 mg/ml)
    • Fludarabine (25 mg/ml)
    • Fulvestrant (50 mg/ml)
    • Gemcitabine (Gemzar) (38 mg/ml)
    • Idarubicin (1 mg/ml)
    • Ifosfamide (IFEX) (50 mg/ml)
    • Irinotecan (20 mg/ml)
    • Mechlorethamine HCL (1 mg/ml)
    • Melphalan (5 mg/ml)
    • Methotrexate (25 mg/ml)
    • Mitomycin C (0.5 mg/ml)
    • Mitoxantrone (2 mg/ml)
    • Oxaliplatin (2 mg/ml)
    • Paclitaxel (Taxol) (6 mg/ml)
    • Paraplatin (10 mg/ml)
    • Pemetrexed Disodium (25 mg/ml)
    • Pertuzumab (30 mg/ml)
    • Raltitrexed (0.5 mg/ml)
    • Rituximab (Rituxan) (10 mg/ml)
    • Temsirolimus (25 mg/ml)
    • Thiotepa (10 mg/ml)
    • Topotecan HCL (1 mg/ml)
    • Trastuzumab (21 mg/ml)
    • Trisenox (1 mg/ml)
    • Velcade (1 mg/ml)
    • Vinblastine (1 mg/ml)
    • Vinorelbine (10 mg/ml)

    Carmustine (3.3 mg/ml) permeation occurred at 60.0 minutes.

    The following hazardous drugs (opioids) and concentration had NO breakthrough detected up to 240 minutes:

    • Fentanyl Citrate Injection (100 mcg/2 ml)
    • Gastric Acid Fluid/Fentanyl Citrate Injection Mix (50/50 Solution)

    Caution: Testing showed a minimum breakthrough time of 60.0 minutes with Carmustine.

    The following hazardous drugs and concentration had NO breakthrough detected up to 240 minutes:

    • Cytovene (10 mg/ml)
    • Retrovir (10 mg/ml)
    • Triclosan (2 mg/ml)
    • Zoledronic Acid (0.8 mg/ml)
    Device Description

    Halyard Purple Nitrile-XTRA* Powder-Free Exam Gloves, Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Fentanyl Citrate in Simulated Gastric Acid are disposable, 12"purple-colored, chlorinated, nitrile, powder-free, textured fingertip, ambidextrous, nonsterile patient examination gloves.

    AI/ML Overview

    The provided text is an FDA 510(k) clearance letter and summary for a medical glove, not an AI-powered medical device. Therefore, many of the requested fields related to AI study design (like "multi-reader multi-case (MRMC) comparative effectiveness study," "standalone performance," "number of experts," etc.) are not applicable and cannot be found in the document.

    However, I can extract the acceptance criteria and performance data for the glove based on the provided information, focusing on the non-clinical and clinical tests described.

    Here's a breakdown of the available information:

    1. Table of Acceptance Criteria and Reported Device Performance

    TestStandardAcceptance CriteriaReported Device Performance
    DimensionsASTM D 6319Length ≥230 mm
    Palm Width Size X-Small: 60 – 80 mm
    Small: 70 - 90 mm
    Med: 85–105 mm
    Large: 100 - 120 mm
    X-Large: 110-130 mm
    XX-Large: 120-140 mm
    Finger thickness ≥0.05 mm
    Palm thickness ≥0.05 mm
    Cuff thickness ≥0.05 mmMeets requirements
    Physical PropertiesASTM D 6319AQL 4.0
    Before Aging: Tensile Strength: ≥14 MPa, Ultimate elongation: ≥500%
    After Aging: Tensile Strength: ≥14 MPa, Ultimate elongation: ≥400%Meets requirements (Tensile strength and elongation before and after aging met requirements)
    Freedom from PinholesASTM D 6319
    ASTM D 5151AQL 2.5%
    No leakageMeets requirements (Meets the 2.5% AQL requirement for leakage)
    Powder FreeASTM D 6124
    ASTM D 6319≤ 2 mg / gloveMeets requirements (Average of 0.4 mg/glove, within the
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1